Both GLP-1 molecules stay off the FDA shortage list
Brand semaglutide and tirzepatide remain resolved on the FDA drug-shortage database. Compounded supply stays legal but under active regulatory attention, so who your provider sources from still matters.
At our latest check, brand semaglutide and tirzepatide both remain resolved on the FDA drug-shortage database — the status that let compounding surge in the first place has now flipped for both molecules.
Compounded supply is still legal, but it operates under active regulatory attention now that the shortage is over. That makes the question of who your provider sources from — an accredited 503A/503B pharmacy versus an opaque supply chain — more important than it was a year ago, not less.
We fold this into every provider's Supply Reliability score. Confirm current status at the source before you assume a specific product is available.
Go deeper: See how we score supply, or see the full best GLP-1 providers board and this week's price tracker.
This is a dated market observation, current as of Jun 28, 2026, and is health and consumer information for education — not medical advice. Prices and supply status change; confirm at the source. See our disclosure.